Japan’s Matsushita Develops New DNA Technology For Drug Response
This article was originally published in PharmAsia News
Matsushita Electric Industrial of Japan reports it has developed a technology that identifies DNA sequence variations electronically for predicting responses to drugs. The system dissolves artificial DNA in a solution instead of attaching it to an electrode, enabling technicians to predict an individual's response to drugs and risk of developing a particular disease. Matsushita refers to the technology as "single nucleotide polymorphisms." (Click here for more
You may also be interested in...
Perrigo is latest consumer health firm to note substantially slower flu rates slammed OTC drug sales during 2020 fourth quarter. Its total cough/cold product sales for the year were off $63m on decreases of $34m in the Americas and $29m in its international markets.
In deal with Altaris Capital, “I don't feel like we got out at any cost,” says Perrigo CEO Murray Kessler. Agreement calls for “a number of mutual long-term relationship components ... including on Rx-to-OTC switches."
FDA and CDC advisory committee members wonder how to use the single-shot J&J vaccine if an ongoing study shows two doses are better than one.